secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-07-16T20:05:45+00:00
Accession:  0001104659-26-084242
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics stockholders approve authorized share increase and reverse split
--------------------------------------------------------------------------------

- Authorized common stock increased from 260M to 600M shares via Certificate of Amendment filed July 16, 2026.
- Reverse stock split approved at ratio 1:10 to 1:50, with exact ratio to be set by board of directors.
- Stockholders approved issuance of shares underlying warrants from April 2026 private placement (up to 16.1M shares) and placement agent warrants.
- Special meeting quorum was 51.5% (62.3M of 120.9M outstanding shares present or represented).
- Proposal 2 (authorized share increase) passed with 24.4M for, 8.7M against; Proposal 3 (reverse split) passed with 44.3M for, 17.8M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926084242/0001104659-26-084242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926084242/tm2620677d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-084242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer